From Seekingalpha · High Alpha Professor · · 30s
TG Therapeutics Sales Boost Raising Revenue Hopes
TG Therapeutics' BRIUMVI sales surge lifts 2024 revenue outlook to $950m.
In brief
TG Therapeutics' BRIUMVI sales surge lifts 2024 revenue outlook to $950m. TG Therapeutics raised 2024 revenue guidance to $950 million after strong BRIUMVI sales growth. Originally reported by Seekingalpha.
BRIUMVI Sales Growth
BRIUMVI sales rose 15% to $227.7 million in Q2, up from $194.8 million in Q1.
“BRIUMVI, a multiple sclerosis drug developed and marketed by TG Therapeutics (TGTX), had US sales of $227.7 million in Q2, up from $194.8 million in Q1, a roughly 15% hike”
Revenue Guidance Raised
TG Therapeutics raised full-year revenue guidance to ~$950 million, approaching blockbuster status.
“Management raised full-year revenue guidance to ~$950 million, near blockbuster status”
Q3 Earnings Focus
Q3 earnings pivotal for margin improvement as net income fell due to elevated R&D and manufacturing expenses.
“Despite revenue momentum, net income fell sharply due to elevated R&D and manufacturing expenses, with Q3 earnings pivotal for margin improvement”
The takeaway
TG Therapeutics raised 2024 revenue guidance to $950 million after strong BRIUMVI sales growth.
